Epistem Announces Partnership with The University of Manchester
Complete the form below to unlock access to ALL audio articles.
Epistem has announced a partnership with Dr Matthew Hardman at The University of Manchester in which novel preclinical models for cutaneous wound healing, developed within Dr Hardman’s laboratory, will be transferred to Epistem.
Epistem and The University of Manchester have been awarded a Knowledge Transfer Partnership (KTP) grant from the Technology Strategy Board and Medical Research Council to optimize, validate and commercialize new preclinical assays for wound repair.
A KTP Associate has been appointed to work within Epistem on the project.
Dr Hardman is a world-leading expert in molecular and cellular aspects of pathological healing and heads a multi-disciplinary research group within the Manchester Healing Foundation Centre for Tissue Regeneration at the University.
Epistem’s Contract Research Services Division provides specialized preclinical and scientific research services to drug development and personal care companies in the areas of oncology, mucositis, inflammatory bowel disease, wound healing and skincare.
Epistem are experienced in commercializing new technologies and the partnership will allow the Company to expand its existing range of wound healing models and to provide a broad, innovative service range.
Dr Hardman, who is based in the University’s Faculty of Life Sciences, said: “It is a real privilege to be awarded the first ever KTP grant to be sponsored by the Medical Research Council. This partnership represents a tremendous opportunity to realize the potential of our work.”
Catherine Booth, Managing Director at Epistem, added: “We are delighted to be working with Dr Hardman, who is a highly regarded wound healing expert, and to be able to provide our customers with access to cutting edge preclinical models.”
